Details for Patent: 9,272,137
✉ Email this page to a colleague
Which drugs does patent 9,272,137 protect, and when does it expire?
Patent 9,272,137 protects ZECUITY and is included in one NDA.
This patent has twenty patent family members in twelve countries.
Summary for Patent: 9,272,137
Title: | Transdermal methods and systems for the delivery of anti-migraine compounds |
Abstract: | Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described. |
Inventor(s): | Anderson; Carter R. (Inver Grove Heights, MN), Morris; Russell L. (Lindstrom, MN), Sebree; Terri B. (Gladwyne, PA) |
Assignee: | Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH) |
Application Number: | 13/105,562 |
Patent Claim Types: see list of patent claims | Compound; Delivery; |
Drugs Protected by US Patent 9,272,137
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,272,137
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007238685 | ⤷ Try a Trial | |||
Brazil | PI0709965 | ⤷ Try a Trial | |||
Canada | 2650412 | ⤷ Try a Trial | |||
Canada | 2935569 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |